TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34750553
Drug: Fenebrutinib 150
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 150 mg daily
Study: 34750553
Drug: Fenebrutinib 50
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 50 mg daily
Study: 34750553
Drug: Fenebrutinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib (all doses)
Study: 34750553
Drug: Fenebrutinib 150
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 150 mg daily and 200 mg twice daily
Study: 34561715
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of estradiol (E2) after observation of a gestational sac and heartbeat (study group)
Study: 34561715
Drug: Continued estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued estradiol (E2) administration until week 12 of gestational age (control group)
Study: 34561715
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups continued progesterone-in-oil administration until week 12 of gestational age
Study: 33604969
Drug: Preemptive clobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive clobetasol 0.05% cream applied twice per day for 8 weeks
Study: 33604969
Drug: Reactive clobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive clobetasol 0.05% cream applied twice per day for 8 weeks
Study: 34289481
Drug: Prosody Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosody Treatment Program (1 hour, once per week for 3 months)
Study: 32334478
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily
Study: 32334478
Drug: 14-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-day regimen of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily
Study: 35685075
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy based on applied behavior analysis (ABA) (control group)
Study: 32621262
Drug: Preventive Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Oral Care Program (POCP) alone
Study: 32621262
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) associated with POCP
Study: 34315495
Drug: Lipoprotein(a) levels
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein(a) levels > 28.72 mg/dL (Q4)
Study: 34315495
Drug: Lipoprotein(a) levels
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein(a) levels > 28.72 mg/dL (Q4) among men
Study: 34315495
Drug: Lipoprotein(a) levels
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein(a) levels > 28.72 mg/dL (Q4) among individuals age > 60 years
Study: 32964537
Drug: Serelaxin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin treatment
Study: 37461117
Drug: Multimodal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal group (virtual care at home including exercise, nutrition counselling, medication consultation)
Study: 37461117
Drug: Socialization group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socialization group (once-weekly phone calls)
Study: 32998148
Drug: Fingerroot (Boesenbergia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingerroot (Boesenbergia rotunda) extract (350 mg extract powder, 3 times daily for 4 weeks)
Study: 32352903
Drug: Serratus anterior
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus anterior plane (SAP) block with 20 mL of 0.2% ropivacaine and 1 μg/mL fentanyl as bolus followed by infusion at 8 mL/h
Study: 32352903
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received saline for both bolus and infusion
Study: 34702956
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid treatment
Study: 36185291
Drug: Integrated yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated yoga therapy intervention during chemotherapy
Study: 36185291
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care during chemotherapy
Study: 33827835
Drug: Perioperative virtual
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative virtual reality‐based stress reduction exercises twice daily
Study: 33827835
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to classical music twice daily
Study: 34956580
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of quick‐acting insulin analogues
Study: 34898333
Drug: Concurrent validity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent validity assessment
Study: 32337796
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to therapy or social supports
Study: 34669096
Drug: In-person consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person consultation offered to women traced by the Genetic Unit (G.U.)
Study: 33555030
Drug: Daratumumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab monotherapy (after Cycle 8)
Study: 34915741
Drug: UGN-101 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-101 (6 once-weekly instillations via retrograde catheter)
Study: 32732703
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of evidence-based medicine
Study: 36244331
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg + Tamsulosin 0.4 mg once daily
Study: 34631986
Drug: Symptom Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom Management Intervention (SMI) with tailored weekly group sessions and mobile health application
Study: 37052334
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 mg orally, three times per day)
Study: 33206270
Drug: Pregabalin with
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin with antioxidants therapy for 8 weeks
Study: 32769505
Drug: Active nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nerve block with 20 ml of 0.375% levobupivacaine and clonidine 0.5 μg/kg
Study: 33008934
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg subcutaneously every 4 weeks
Study: 33008934
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Lebrikizumab with pirfenidone)
Study: 32111310
Drug: Conventional cage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cage (CC) housing system
Study: 33233227
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup (40 g)
Study: 33233227
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 g)
Study: 33639349
Drug: 20% biochar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% biochar litter treatment
Study: 34706556
Drug: MEDI5884 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI5884 (50, 100, 200, 350, or 500 mg SC)
Study: 34706556
Drug: MEDI5884 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI5884 (500 mg SC)
Study: 35681264
Drug: Single immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single immune checkpoint inhibitor (ICI)
Study: 35681264
Drug: Single ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ICI plus chemotherapy
Study: 34155332
Drug: 90 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/day of baclofen
Study: 32676976
Drug: Keguan-1 19.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keguan-1 19.4 g twice daily plus control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Study: 32676976
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily)
Study: 33757646
Drug: Renin–angiotensin–aldosterone system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin–angiotensin–aldosterone system blockers
Study: 34107828
Drug: One IPL
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One IPL treatment followed by three diode laser treatments
Study: 34107828
Drug: Two IPL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two IPL treatments followed by three diode laser treatments
Study: 34107828
Drug: Three IPL
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three IPL treatments followed by three diode laser treatments
Study: 36339420
Drug: 1, 2,
Normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, 4, 8, or 12 µg/day CG beta plus rFSH
Study: 36339420
Drug: CG beta
Normalized name: CG-200745
DrugBank: CG-200745 (DB12259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG beta (highest dose group)
Study: 32374623
Drug: NUC-1031 (725
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-1031 (725 mg/m2)/cisplatin (25 mg/m2)
Study: 32374623
Drug: gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000 mg/m2)/cisplatin (25 mg/m2)
Study: 32316391
Drug: Nucleotide-depleted mycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide-depleted mycoprotein (L-NU)
Study: 32316391
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (H-NU and L-NU)
Study: 35972834
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with glucocorticosteroid and fusidic acid
Study: 35972834
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream with fusidic acid
Study: 34062140
Drug: Voclosporin (23.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voclosporin (23.7 mg twice daily and 39.5 mg twice daily)
Study: 32811741
Drug: Johrei treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johrei treatment
Study: 34388360
Drug: BI 695501
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695501 (40 mg/0.8 mL formulation)
Study: 34388360
Drug: Adalimumab reference
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab reference product (40 mg/0.4 mL or 40 mg/0.8 mL)
Study: 35338469
Drug: Upacicalcet 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upacicalcet 0.01 mg
Study: 35338469
Drug: Upacicalcet 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upacicalcet 0.1 mg
Study: 35338469
Drug: Upacicalcet 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upacicalcet 1.0 mg
Study: 35338469
Drug: Upacicalcet 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upacicalcet 2.5 mg
Study: 35718502
Drug: Placebo (Jingfang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Jingfang Granules simulation agent)
Study: 32048918
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point dry needling (TDN) combined with manual therapy (MT) and exercise (Ex)
Study: 32048918
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) and exercise (Ex)
Study: 34252914
Drug: Placebo-administered agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-administered agent (subcutaneous, endovenous, or oral)
Study: 34252914
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of eptinezumab (anti-calcitonin gene-related peptide monoclonal antibody)
Study: 34252914
Drug: Oral topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral topiramate
Study: 34252914
Drug: Subcutaneous monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous monoclonal
Study: 34252914
Drug: Multiple head
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple head injections (botulinum toxin)
Study: 33065733
Drug: Total opioid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total opioid exposure increase (per mg/kg/d)
Study: 33065733
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication or sedative administered in the previous 4 hours
Study: 33065733
Drug: No progressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No progressive physical therapy or ambulation schedule
Study: 35718625
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus infusion (PIBI)
Study: 32223116
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation alone
Study: 34293738
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate (FC) 1 tablet (1-g equivalent to 210 mg ferric iron) TID (3 g/day)
Study: 34293738
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate (FC) 2 tablets BID (4 g/day)
Study: 34605026
Drug: β‐OHB supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐OHB supplementation (30 mL or 12 g, thrice-daily for 14 days)
Study: 35551683
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg, q.d. for 4 weeks
Study: 36255254
Drug: 0.05% Dapivirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% Dapivirine gel administered rectally using an applicator (2.5 g)
Study: 36255254
Drug: Dapivirine gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine gel self-administered as lubricant (up to 10 g)
Study: 36361215
Drug: Integrative cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative cognitive function improvement program administered to CN and MCI groups for six weeks.
Study: 34180278
Drug: CTFA-GRT (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTFA-GRT (group reminiscence therapy based on Chinese traditional festival activities)
Study: 34918965
Drug: Restrictive Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive Fluid Therapy (Control)
Study: 34918965
Drug: Both GDFT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both GDFT and Restrictive Fluid Therapy
Study: 32268439
Drug: Pre-emptive administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive administration of ibuprofen or paracetamol
Study: 33074393
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity laser therapy (HILT) + exercise therapy (ET)
Study: 33074393
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser (PL) + exercise therapy (ET)
Study: 32187789
Drug: biomedically focused
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biomedically focused education and exercise therapy
Study: 35359035
Drug: 4% mangosteen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% mangosteen gel
Study: 35102171
Drug: SAMiRNA-AR68 (AR68)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMiRNA-AR68 (AR68) at a low dose of 0.5 mg/ml applied three times per week for 24 weeks
Study: 35102171
Drug: SAMiRNA-AR68 (AR68)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMiRNA-AR68 (AR68) at a high dose of 5 mg/ml given once per week for 24 weeks
Study: 33737199
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (SL-BUP)
Study: 33737199
Drug: 7-day extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day extended-release injectable buprenorphine (CAM2038, XR-BUP)
Study: 33908636
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg intravenously every 4 weeks (continuously treated)
Study: 33908636
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg intravenously every 4 weeks (re-treated after treatment interruption)
Study: 33908636
Drug: Placebo maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maintenance (during treatment interruption)
Study: 34171279
Drug: 7+3 (cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7+3 (cytarabine and daunorubicin chemotherapy)
Study: 32577871
Drug: EMR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMR with the application of 0.3 ml of N-butyl-2-cyanoacrylate + methacryloxysulfolane—Glubran 2®
Study: 32367748
Drug: Baihe Gujin
Normalized name: Yujin (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baihe Gujin decoction combined with anti-tuberculosis therapy
Study: 32367748
Drug: Anti-tuberculosis treatment
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis treatment
Study: 33165125
Drug: Time‐varying reactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time‐varying reactive urine toxicology results for stimulants
Study: 33951415
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg biweekly subcutaneous)
Study: 35978289
Drug: Multi-faceted exercise
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-faceted exercise intervention (thrice weekly aerobic and progressive resistance training, reducing sedentary time by 30 min)
Study: 35818509
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day aspirin
Study: 33334939
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline 100 mg twice daily plus low-dose oral prednisone 5 mg once daily
Study: 33334939
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline 100 mg twice daily plus placebo
Study: 33584074
Drug: Quiklean® (32-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quiklean® (32-tablet sodium phosphate)
Study: 33584074
Drug: Klean‐Prep/Dulcolax® (2-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klean‐Prep/Dulcolax® (2-L polyethylene glycol/bisacodyl)
Study: 32250536
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (degludec)
Study: 34647404
Drug: Tirzepatide 5
Normalized name: tirzepatide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 5 mg (weeks 1-8)
Study: 34647404
Drug: Tirzepatide 10
Normalized name: tirzepatide 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 10 mg (2.5 mg weeks 1-2; 5 mg weeks 3-4; 10 mg weeks 5-8)
Study: 34647404
Drug: Tirzepatide 15
Normalized name: tirzepatide 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 15 mg (5 mg weeks 1-2; 10 mg weeks 3-6; 15 mg weeks 7-8)
Study: 32180266
Drug: Wiping twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wiping twice with pressure ≥40 mmHg
Study: 34059080
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of umbilical cord-derived Wharton's jelly (WJ)
Study: 35948970
Drug: We Can
Normalized name: CAN-106
DrugBank: CAN-106 (DB18389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We Can Quit intervention with free nicotine replacement therapy (NRT)
Study: 32446306
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment group (n = 28)
Study: 34109778
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 buccal spray (2000 U, n=30) for six weeks
Study: 34109778
Drug: Oral drops
Normalized name: Oral Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drops (2000 U, n=30) for six weeks
Study: 34109778
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (300,000 U, n=30)
Study: 33147541
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nano-curcumin for two months
Study: 36174766
Drug: F2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: F2 group (etch-mineralizing solution with 10 mg/ml sodium fluoride)
Study: 36174766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (35% phosphoric acid gel treatment)